News

Stay up to date on the latest company news and scientific headlines.

Interleukin Genetics Deploys ILUSTRATM Inflammation Management Program with mPulse Mobile Employees

Enhanced Benefit Can Deliver Significant Health and Economic Value by Targeting Chronic Inflammation

WALTHAM, MA – February 23, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has entered into a relationship with mPulse Mobile, a leader in mobile health engagement, to offer the ILUSTRA Inflammation Management Program to their employees as an enhancement to the company’s employee benefits plan.

“This innovative program is a clear match with our company values and mission,” said Brian Chudleigh, Chief Financial Officer at mPulse Mobile. “Affecting behavioral change toward a healthy lifestyle is the key to realizing long-term health, wellness and reduced healthcare costs. I am impressed with the ILUSTRA program […]

IG and PBGH Forge Relationship To Bring ILUSTRATM To Pittsburgh Employers

WALTHAM, MA – Feb 15, 2017Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has entered into a relationship with the Pittsburgh Business Group on Health (PBGH) to offer the ILUSTRA™ Inflammation Management Program to PBGH employer-members in the Pittsburgh area as part of a company’s enhanced employee benefits plan.

“PBGH is the region’s leading employer-led coalition designed to drive transparency in health care data, cost and quality. Western Pennsylvania has a history of health care innovation and we are delighted to be working together to build on this heritage,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “This relationship advances our commercial strategy by providing […]

Interleukin Genetics Reports Third Quarter 2016 Financial Results

WALTHAM, Mass. – November 15, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial results for its fiscal third quarter of 2016, ended September 30, 2016, and provided a corporate update.

“Interleukin Genetics continued to advance our commercial plan to drive market adoption of our Inflammation Management Program, which we recently relaunched as ILUSTRA™, that includes the genetic risk test (formerly known as PerioPredict®) that enables the identification and improved management of inflammation for individuals who may have a genetic predisposition to over-produce Interleukin-1 (IL-1), a key mediator of inflammation,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.  “During the third quarter, our focus was on integrating our expanded team to drive our commercial strategy and refining our […]

Interleukin Genetics Announces Conference Call to Discuss Third Quarter 2016 Financial Results

WALTHAM, MA – November 9, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and webcast on Tuesday, November 15, 2016, at 8:30 a.m. Eastern Time to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2016.

Tuesday, November 15th, 8:30 a.m. Eastern Time
Dial in (domestic):                   877-324-1976
Dial in (international):            631-291-4550
Conference ID:                         13333032
A live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com.  The webcast will be archived following the call at www.ilgenetics.com.

About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals to prevent certain […]

Interleukin Genetics Launches the ILUSTRA Inflammation Management Program

Easy-to-deploy benefit enhancement can deliver significant health and economic value by targeting chronic inflammation

WALTHAM, Mass., November 3, 2016 — Interleukin Genetics, Inc. (OTCQB:ILIU) a life science company focused on the genetics of chronic inflammation, today unveiled the  ILUSTRA™ Inflammation Management Program. The program targets individuals at elevated risk for severe periodontitis due to a genetic tendency to over-produce inflammation. Under supervision of a licensed dentist or physician, ILUSTRA is offered by employers and through select insurance carriers as an enhanced benefit that has potential to provide significant health and economic value by improving the management of chronic inflammation.

ILUSTRA incorporates three components: 1) a simple yet technologically advanced genetic risk test; 2) targeted education to healthcare professionals to individualize care […]

Interleukin Genetics Cites Role in Key Antisense Drug Trial Published in The Lancet

Interleukin’s Genetic Test Patterns Provide Key Genetic Data in Clinical Studies

WALTHAM, Mass., September 22, 2016 — Interleukin Genetics, Inc. (OTCQB: ILIU) a life science company focused on the genetics of chronic inflammation, today announced their contribution to the key publication in The Lancet (September 21, 2016) of the article “Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomized, double blind, placebo-controlled, dose ranging trials.” The article provides strong evidence that the antisense drug IONIS-APO(a)-LRX is well tolerated and capable of achieving substantial reductions in Lp(a) concentrations in patients. The drug is intended, in part, to reduce the risk for secondary cardiovascular events in individuals with elevated Lp(a).

“This prestigious publication shows the potential for Interleukin-1 genetic variations […]

Interleukin-1 Genetic Variations Influence Obesity Effect in Periodontal Disease Progression

Interleukin Genetics Provides New Evidence for Role of IL-1 Genetic Variations in Determining Impact of Obesity on Chronic Inflammatory Diseases

Waltham, Mass (August 23, 2016) – Interleukin Genetics, Inc. (OTCQB: ILIU) a life science company focused on the genetics of chronic inflammation, today announced the publication of the article “Influence of Obesity on Periodontitis Progression is Conditional on IL-1 Inflammatory Genetic Variation” in the Journal of Periodontology (http://www.joponline.org/doi/abs/10.1902/jop.2016.160408 ).The article is the result of a scientific collaboration with key researchers at Boston University and strongly supports the value of Interleukin-1 (IL-1) genetics in amplifying the negative impact of obesity.

“Interleukin Genetics continues to build scientific support for the clinical value of IL-1 genetic information,” said Ken Kornman, Chief Scientific Officer. […]

Interleukin Genetics Reports Second Quarter 2016 Financial Results

WALTHAM, Mass. – August 16, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial results for its fiscal second quarter of 2016, ended June 30, 2016, and provided a corporate update.

“The second quarter was significant for Interleukin Genetics, as we continue to advance our commercial plan to drive market adoption of PerioPredict®, our genetic test that identifies individuals with an increased risk for severe and progressive periodontitis due to a life-long genetic predisposition to over-produce Interleukin-1 (IL-1), a key mediator of inflammation,” said Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics.  “Since the beginning of the year, we’ve made progress on both tracks of our commercial strategy, signing new licensing agreements for PerioPredict with both a large self-insured […]

Interleukin Genetics Announces Conference Call to Discuss Second Quarter 2016 Financial Results

WALTHAM, MA – August 9, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and webcast on Tuesday, August 16, 2016, at 8:30 a.m. Eastern Time to provide a corporate update and discuss the Company’s financial results for the second quarter ended June 30, 2016.

Tuesday, August 16th, 8:30 a.m. Eastern Time

Dial in (domestic):                 877-324-1976
Dial in (international):            631-291-4550
Conference ID:                       62562552

A live webcast will also be available at the Investors section of the Company’s website at www.ilgenetics.com.  The webcast will be archived following the call at www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (OTCQB: ILIU) […]

Interleukin Genetics Strengthens Commercial Leadership with Key Appointments

Stephan Toutain appointed Chief Commercial Officer and Mary Hiter appointed Director of Marketing

WALTHAM, Mass. – August 3, 2016 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life science company focused on the genetics of chronic inflammation, today announced the appointment of two senior leaders to enhance its commercial team and capabilities. Stephan Toutain will join Interleukin as Chief Commercial Officer, and Mary Hiter will become Director of Marketing, both newly created roles at the company. Mr. Toutain and Ms. Hiter will join Interleukin later this month.

“These appointments are an important step in our strategy to drive the market adoption of our PerioPredict® Genetic Risk Test and Patient Engagement Platform. Stephan is a seasoned business leader and an experienced sales and marketing executive who […]